<DOC>
	<DOCNO>NCT01330901</DOCNO>
	<brief_summary>This study aim investigation efficacy safety ustekinumab ( monoclonal antibody interleukin 12 23 ) treatment patient active ankylose spondylitis ( AS ) fulfil modified New York criterion inadequate response standard therapy non-steroidal anti-inflammatory drug ( NSAIDs ) tolerate contraindication NSAIDs .</brief_summary>
	<brief_title>Ustekinumab Treatment Patients With Active Ankylosing Spondylitis</brief_title>
	<detailed_description>This study prospective , open-label , proof-of-concept clinical trial conduct referral center patient AS Berlin . Eligible patient treat ustekinumab 90 mg give subcutaneously week 0 , 4 , 16 . The entire study period account 28 week . Assessment primary outcome parameter perform week 24 . The patient closely monitor throughout study total 9 visit .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>1 . Age ≥18 year . 2 . Definite diagnosis AS accord modify New York criterion . 3 . History inadequate response ≥2 NSAIDs take least 2 week NSAIDs intolerance/contraindication . 4 . Active disease define BASDAI value ≥4 screen despite concomitant treatment NSAID without NSAIDs case intolerance/contraindication . 5 . Able willing give write informed consent comply requirement study protocol . 6 . If female : either childbearing potential ( menopausal since 1 year surgically sterile ) willing able practice reliable method contraception . 7 . If male : either childbearing potential ( surgically sterilize , e.g . vasectomy ) willing able practice reliable method contraception . 8 . If NSAIDs : dose must stable least 2 week prior baseline . 9 . If oral steroid : dose must exceed 10 mg ( prednisolone equivalent ) per day must stable least 4 week prior baseline . 10 . If methotrexate : dose must exceed 25 mg per week must stable least 4 week prior baseline , must stable 4 week prior baseline . 11 . If analgesic : dose must stable least 2 week prior baseline . 1 . The female subject pregnant lactating . 2 . Patients chronic inflammatory articular disease systemic autoimmune disease . 3 . History inadequate response previous antitumor necrosis factor ( TNF ) α therapy . 4 . Previous treatment biologics TNF α blocker . 5 . Treatment investigational drug within 4 week 5 halflife drug ( whichever longer ) prior baseline . 6 . Treatments disease modify antirheumatic drug ( DMARDs ) methotrexate within 4 week prior screen ( 8 week leflunomide 4 week standard cholestyramine washout ) . 7 . Treatment intravenous , intramuscular intraarticular/periarticular steroid within 4 week prior screen . 8 . Any active current infection , history recurrent clinically significant infection , infection require treatment antibiotic within 4 week prior baseline . 9 . Current clinical sign symptom suggestive tuberculosis . 10 . Positive interferon gamma release assay ( IGRA ) test screen and/or abnormal chest xray ( perform screen within 3 month prior screen ) suggestive past present tuberculosis ( positive xray ) . Patients positive IGRA test negative chest xray without clinical symptom suggestive tuberculosis may participate study initiation standard prophylactic antimycobacterial treatment . 11 . Chronic infection hepatitis B C , history human immunodeficiency virus infection . 12 . Primary secondary immunodeficiency . 13 . Actual malignancy history malignancy curative treatment within 5 year prior screen , except successfully treat nonmetastatic squamouscell basalcell carcinoma carcinoma situ cervix . 14 . Evidence severe uncontrolled gastrointestinal , hepatic , renal , pulmonary , cardiovascular , nervous endocrine disorder . 15 . Any condition make patient unsuitable opinion investigator participation current study . 16 . Patients history severe psychiatric illness , might interfere patient 's ability understand requirement study assessment . 17 . Diagnosis fibromyalgia . 18 . Alcohol abuse illegal drug consume last 12 month . 19 . Vaccination live vaccine within 12 week prior baseline . 20 . Known hypersensitivity component study medication . 21 . Clinically significant laboratory abnormality 22 . Patients institutionalised due regulatory juridical order . 23 . Patients contraindication magnetic resonance imaging ( MRI )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>